Fenebrutinib linked to reduced lesion activity, higher CSF penetration in MS at 12 weeks

In relapsing forms of multiple sclerosis, fenebrutinib treatment led to reduction of lesion activity and resulted in higher penetration into cerebrospinal fluid at 12 weeks, according to research from ECTRIMS 2023.
“Rapidly acting therapies are needed for multiple sclerosis that can control both the acute inflammation that underlies relapses and the chronic inflammation that is involved in non-relapsing progressive disease,” Amit Bar-Or, MD, FRCP, FAAN, FANA, director of the Center for Neuroinflammation and Neurotherapeutics at the University of Pennsylvania Perelman School of

In relapsing forms of multiple sclerosis, fenebrutinib treatment led to reduction of lesion activity and resulted in higher penetration into cerebrospinal fluid at 12 weeks, according to research from ECTRIMS 2023.
“Rapidly acting therapies are needed for multiple sclerosis that can control both the acute inflammation that underlies relapses and the chronic inflammation that is involved in non-relapsing progressive disease,” Amit Bar-Or, MD, FRCP, FAAN, FANA, director of the Center for Neuroinflammation and Neurotherapeutics at the University of Pennsylvania Perelman School of